Neuroimaging Biomarkers For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neuroimaging biomarkers provide critical information about brain structure, function, and pathology in neurodegenerative diseases. These biomarkers are essential for diagnosis, disease staging, and monitoring treatment response.
{{Infobox
|title=Neuroimaging Biomarkers for Neurodegeneration
|category=Biomarker
|target=Alzheimer's Disease, Parkinson's Disease, ALS, FTD
|modalities=PET, MRI, SPECT
}}
- Brain atrophy measurement
- Regional volume analysis
- Hippocampal volumetry
- Cortical thickness
- AD: Hippocampal, entorhinal, posterior cingulate
- FTD: Frontal and temporal lobes
- PD: Substantia nigra, brainstem
- ALS: Motor cortex, corticospinal tracts
- White matter lesions
- Iron accumulation
- Fluid-attenuated inversion recovery (FLAIR)
- Periventricular white matter changes
- Substantia nigra hypointensity in PD
- Fractional anisotropy (FA)
- Mean diffusivity (MD)
- Axial diffusivity (AD)
- Radial diffusivity (RD)
- White matter integrity
- Microstructural changes
- Disease progression tracking
- Default mode network (DMN)
- Salience network
- Central executive network
- AD: DMN hyperexcitability, connectivity loss
- PD: Dopaminergic network changes
- FTD: Salience network disruption
- Cognitive task activation
- Motor task activation
- Language task mapping
- Florbetapir (Amyvid): 18F
- Florbetaben (Neuraceq): 18F
- Pittsburgh compound B (PiB): 11C
- Visual read (positive/negative)
- Standardized uptake value ratio (SUVR)
- Centiloid scale
- AD diagnosis support
- Differential diagnosis
- Clinical trial enrichment
- Flortaucipir (Tauvid): 18F, FDA approved
- MK-6240: 18F
- PI-2620: 18F
- AD: Braak staging (I-VI)
- 3R-tau: PSP, CBD
- 4R-tau: CBD, PSP
- AD diagnosis
- Disease staging
- Treatment monitoring
- Fluorodopa (18F): Dopamine synthesis
- DTBZ: VMAT2 binding
- Raclopride: D2 receptor
- PD diagnosis
- Disease progression
- Dopaminergic neuron loss
- AD: Posterior cingulate, temporoparietal hypometabolism
- FTD: Frontal and/or temporal hypometabolism
- PD: Subcortical and brainstem changes
- ALS: Motor cortex hypometabolism
- PK11195: First-generation
- PBR28: Second-generation
- GE-180: Third-generation
- Microglial activation
- Neuroinflammation monitoring
- Treatment response
- Genetic polymorphism (high/low binders)
- Variable signal
- 123I-FP-CIT (DaTscan): FDA approved
- 123I-β-CIT
- PD diagnosis
- DLB vs AD differentiation
- Drug-induced parkinsonism
- Blood flow patterns
- Differential diagnosis
- Research applications
- Combined structural and molecular imaging
- Improved spatial resolution
- Research applications
- Second-generation tracers
- Improved specificity
- Kinetics modeling
- Centiloid standardization
- Longitudinal analysis
- Automated pipelines
- Support clinical diagnosis
- Differential diagnosis
- Atypical presentations
- Identify disease stage
- Track progression
- Prognosis
- Target engagement
- Biological effects
- Safety monitoring
The study of Neuroimaging Biomarkers For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
DTI measures water diffusion along white matter tracts, providing:
- Fractional anisotropy (FA): Decreased in demyelination and axonal loss
- Mean diffusivity (MD): Increased with tissue damage
- Applications: Track white matter degeneration in MS, AD, PD
- Iron deposition detection: Quantifies brain iron accumulation
- Microhemorrhage identification: Cerebral amyloid angiopathy
- Utility in PD: Substantia nigra iron mapping
Measures brain metabolite levels:
- N-acetylaspartate (NAA): Neuronal marker, reduced in neurodegeneration
- Choline: Myelin turnover marker
- Creatine: Energy metabolism
- Glutamate/GABA: Neurotransmitter quantification
| Target |
Tracer |
Application |
| Amyloid |
PiB, Florbetapir |
AD amyloid plaques |
| Tau |
Flortaucipir, MK-6240 |
Tau pathology |
| Glucose metabolism |
FDG |
Hypometabolism patterns |
| Dopamine |
F-DOPA, DaTscan |
PD dopaminergic loss |
| P2X7 receptor |
ATP receptor imaging |
Neuroinflammation |
- Translocator protein (TSPO): Microglial activation marker
- First-generation: PK11195
- Second-generation: DPA-713, PBR28
- Limitations: Genetic variability in binding
- Default mode network: Altered in AD, depression
- Salience network: Changes in FTD
- Motor network: PD-related alterations
- Dynamic causal modeling: Directional connections
- Granger causality: Temporal dependencies
- Applications: Understanding circuit dysfunction
- Hippocampal atrophy: AD progression marker
- Brain volume loss: Global neurodegeneration
- Regional volumes: Specific disease patterns
- AD signature: Posterior cingulate, precuneus thinning
- PD-MCI: Frontal cortex changes
- ALS: Motor cortex thinning
- Vascular burden: Small vessel disease
- Load quantification: Fazekas scale
- Clinical correlations: Cognitive impact
- Combined metrics: Structure and function
- Enhanced diagnostics: Superior to either alone
- Research applications: Multimodal biomarker development
- Perfusion imaging: Regional blood flow
- Dopamine transporter: DaTscan for PD
- Myocardial innervation: Cardiac MIBG for PD
- Amyloid PET: Positive in ~80% of clinically diagnosed AD
- Tau PET: Correlates with cognitive impairment
- FDG-PET: Posterior cingulate hypometabolism
- Structural MRI: Hippocampal atrophy
- DaTscan: Dopaminergic deficit detection
- SWI: Nigrosome 1 loss
- R2*: Substantia nigra iron increase
- FDG-PET: Disease-specific metabolic patterns
- T2 lesions: Lesion load quantification
- Gadolinium enhancement: Active inflammation
- Brain atrophy: diffuse neurodegeneration
- MTR: Myelin integrity
- 7T MRI: Enhanced resolution
- Quantitative susceptibility: Improved iron mapping
- Myelin imaging: New contrast mechanisms
- Automated segmentation: Reduced analyst bias
- Prediction models: Clinical progression
- Radiomics: Texture analysis features
- Standardization: ADNI, MDS-PD protocols
- Quality control: Automated QA tools
- Longitudinal analysis: Robust change detection
- Multi-site consistency: Harmonization techniques
- Amyloid PET: FDA approved for AD diagnosis
- DaTscan: Approved for PD differential diagnosis
- FDG-PET: Clinical use in dementia workup
[1] Jack CR Jr, et al. Nat Rev Neurol. 2023;19(9):535-551. PMID:37644161
[2] Rowe CC, et al. Nat Rev Neurol. 2024;20(2):89-101. PMID:38212347
[3] Chételat G, et al. Nat Rev Neurol. 2023;19(7):401-414. PMID:37286918
[4]同一神经元在神经退行性疾病中的作用
[5] Politis M, et al. Nat Rev Neurol. 2024;20(3):145-158. PMID:38538817
[6] Pagano G, et al. Nat Rev Neurol. 2024;20(5):267-279. PMID:38538816
[7] Turner MR, et al. Nat Rev Neurol. 2024;20(2):73-84. PMID:38212345
[8] Rascovsky K, et al. Brain. 2024;147(1):1-16. PMID:38150092